For patients with HER2-negative tumours they found genomic features associated with response to chemotherapy typically correlated with proliferation, TP53 mutation, tumour mutational burden, chromosomal instability, BRCA, HRD and APOBEC associated mutational signatures. Here, ERBB2 is linked to neoplasm.